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Abstract
Background: Accumulating evidence indicate that B cells can exhibit pro- or anti-inflammatory activities. Similar to
interleukin (IL)-10–competent B cells, we recently showed that transforming growth factor (TGF)-β1-producing
regulatory B cells limit the induction of autoimmune neuroinflammation in mice, making them potentially
important in maintaining peripheral immune tolerance in central nervous system inflammatory demyelinating
disorders such as multiple sclerosis.
Methods: In this study, we compared B cell production of TGF-β1 and IL-10, the two most studied regulatory
cytokines, and the pro-inflammatory B cell-derived IL-6 and tumor necrosis factor cytokines under basal conditions and
following polyclonal stimulation with dual B cell receptor (BCR) cross-linking and Toll-like receptor (TLR)9 engagement.
Results: We showed that resting TGF-β1–producing B cells fall within both the naïve (CD27−) and memory (CD27+)
B cell compartments. We found no spontaneous B cell-derived IL-10, IL-6 or tumor necrosis factor (TNF) production.
Human B cell activation with anti-Ig antibodies plus CPG-B leads to only modest IL-10 production by memory CD19
+CD27+ B cells while expression levels of IL-6 and TNF by both naive and memory B cells were strongly induced.
Remarkably, stimulated B cells showed significantly reduced capacity to produce TGF-β1.
Conclusions: These findings indicate that B cell activation may facilitate the development of excessive immune
responses and autoimmunity by restricting B cell-derived TGF-β1 production by resting B cells and favoring in turns
the proinflammatory actions of activated cytokine-producing B cells.
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Background
Recent years have seen a significant increase in the inter-
est of the roles of B cells in autoimmune diseases such
as multiple sclerosis (MS), not only as precursors of
antibody-producing plasma cells [1, 2], but also as key
regulators of T cell activation and differentiation through
their antigen presentation function [3, 4] and cytokine
production [3, 5, 6]. To date, the strongest evidence for
B cells playing a crucial role in the immune pathology of
MS arises from clinical trials uncovering the effect and
potency of anti-CD20 B cell-depleting therapies (BCDT)
[7–10]. In addition, a growing body of experimental
studies suggests that activation of antigen-driven B cells
can lead to central nervous system (CNS) autoimmune
reactions [11, 12] and that B cells in MS may be inherently
polarized towards a functional proinflammatory pheno-
type [6, 13–16]. Remarkably, some recent work has
reported evidences of increased proinflammatory cytokine
responses of B cells from MS patients upon non-CNS
specific (i.e., CpG DNA) stimulation [17–19], suggesting
that abnormal B cell effector cytokine responses in MS
patients are not restricted to specific autoreactive B cells.
Recent research indicates that the activation status
dictates the diverse roles a respective B cell may play in
MS pathogenesis [13]. Activated B cells, in particular
memory B cells, are more pathogenic than naïve ones.
While memory B cells are more easily activated to
produce proinflammatory cytokines such as tumor
necrosis factor (TNF), interleukin (IL)-6, and granulo-
cyte macrophage-colony stimulating factor (GM-CSF),
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naïve B cells preferentially secrete the regulatory
cytokine IL-10 [6, 17]. Although the current data
support the conceptual idea of a prominent involvement
of activated proinflammatory B cells in MS pathogenesis,
accumulating experimental and clinical findings indicate
that not all B cells play a pathogenic role in MS [20].
Defects in regulatory B cell functions have been docu-
mented in MS patients [13, 17, 21–23], suggesting that a
disrupted balance between proinflammatory and sup-
pressive B cell properties may be particularly relevant to
the regulation of CNS autoimmunity. While exacerba-
tion of MS activity as a result of anti-CD20-mediated B
cell depletion has not yet been documented, increased
proinflammatory monocytic activity following B cell de-
pletion has been reported in experimental autoimmune
encephalomyelitis (EAE) [24], a model for MS, and more
recently in some anti-CD20 monoclonal antibodies-
treated MS patients [25]. Evidence that BCDT also de-
pletes potential protective B cell responses comes from
clinical reports showing that infusion of the monoclonal
anti-CD20 antibody Rituximab for autoimmunity has led
to severe exacerbation of colitis and the spontaneous
onset of colitis and psoriasis readily after the initiation
of treatment [26–29]. Management of non-Hodgkin’s
lymphoma with Rituximab has also been associated with
the onset of autoimmunity [30]. Interestingly, in MS,
treatment with Atacicept, a decoy receptor for the B cell
growth factors B-cell activating factor (BAFF) and a
proliferation-inducing ligand (APRIL), was found to
exacerbate MS, possibly by altering regulatory B cell
functions [31]. These cautionary data emphasize that
pan depletion of B cells can be deleterious in some situa-
tions, and therefore supports further development of a
therapeutic option for treating MS patients that spares
regulatory B cell functions [32].
One of the first studies illustrating a decreased regula-
tory B cell function in patients with an autoimmune
condition was performed in the context of MS [17]. De-
creased IL-10 production was seen upon B cell activa-
tion via CD40, or B cell receptor (BCR) in conjunction
with CD40 [17], or Toll-like receptor (TLR)9 [21, 23],
indicating a general alteration of B cell functions in MS
rather than a defect in certain activation signaling path-
ways. Similar to IL-10-producing B cells [33–35], trans-
forming growth factor (TGF)-β1-producing regulatory B
cells have recently been shown by our group to restrain
the initiation phase of experimental autoimmune neuro-
inflammation [36], making them potentially important in
maintaining peripheral immune tolerance in organ-
specific autoimmune disease such as MS. Consistent
with this premise, recent evidence indicates that B cell
subpopulations expressing TGF-β can control regulatory
T cell induction, immune tolerance promotion, and/or in-
nate and adaptive immune response suppression [37–50].
With regards to the importance of TGF-β1-producing B
cells in the regulation of CNS autoimmunity, evaluating
whether B cell activation governs TGF-β1 expression by
human B cells may provide a better understanding of the
contribution and mechanism of regulatory B cell functions
in autoimmune manifestations.
Here, we measured B cell production of TGF-β1 and
IL-10, the two most studied regulatory cytokines, and
the proinflammatory B cell-derived IL-6 and TNF
cytokines under basal conditions and following poly-
clonal stimulation with dual BCR cross-linking and
TLR9 engagement. Spontaneous TGF-β1 production by
resting B cells was observed in both the naïve (CD27−)
and memory (CD27+) B-cell compartments. In contrast,
we found that IL-10 production was negligible in B cells
under basal culture conditions. Likewise, unstimulated B
cells did not produce the proinflammatory cytokines IL-
6 and TNF. Remarkably, B cells stimulated with com-
bined anti-Ig antibodies + CpG-B showed decreased
TGF-β1 production capacity. We also noted that once
activated, a fraction of memory, but not naïve, B cells
expressed low, but significant, IL-10 levels. Finally, B cell
stimulation strongly enhanced production of IL-6 and
TNF by B cells. These findings indicate that B cell acti-
vation may contribute to immunological abnormalities
seen in autoimmune disorders such as MS by restricting
the regulatory functions of resting TGF-β1-producing B




Peripheral blood B cells were isolated from buffy coats
of blood from healthy volunteers (five male and one
female, median age 55 years, range 29–67 years) pro-
vided by the Geneva Hospital Blood Transfusion Center.
In accordance with the ethical committee of the Geneva
Hospital, the blood bank obtained informed consent
from the donors that a part of their blood would be used
for research purposes.
Cell preparation and B cell purification
Highly purified CD19+ B cells (<90% purities) were iso-
lated from the mononuclear fraction using negative selec-
tion microbeads (Human B cell Enrichment Kit; EasySep
19054, STEMCELLTechnologies).
Reagents
AffiniPure F(ab')2 Fragment Goat Anti-Human IgA + IgG
+ IgM (H + L) (anti-Ig) was from Jackson ImmunoRe-
search. ODN 2006 (ODN 7909) Class B CpG oligonucleo-
tide; a human TLR9 ligand, was purchased from
Invivogen. X-Vivo 15 medium for culturing B cells was
from Lonza.
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Staining and immunofluorescence analysis
Cells (106 cells/mL) were suspended in complete
medium (X-Vivo 15 medium containing 200 mg/mL
penicillin, 200 U/mL streptomycin, 4 mM L-Glutamine
and 1 mM Sodium Pyruvate, all from Gibco) in the pres-
ence of CpG-B 2006 (10 μg/mL, Tib Molbiol) and anti-
Ig (10 μg/mL) in 24-well flat-bottom plates for 24 h, at
37 °C. During the last 5 h, cells were additionally stimu-
lated with 50 ng/mL of phorbol myristate acetate
(PMA), 1 nM ionomycin (Sigma-Aldrich), and 2 mM
monensin (all from eBioscience). Viability was assessed
using a UV Live/Dead Fixable dead cell staining kit
(Invitrogen). Nonspecific antibody (Ab) interactions of
Fc receptors (FcRs) on cells were limited using TruStain
FcX reagent (BioLegend), as per the manufacturer’s in-
structions. Cells were stained with antibodies to the fol-
lowing cell surface markers: CD19–FITC, CD19–APC,
CD27–FITC, and CD27–PE (all from BioLegend),
isotype-matched controls were from Biolegend or BD
Pharmingen. After washing, cells were fixed and perme-
abilized using a Fix and Perm kit (Invitrogen) and
stained by intracellular staining (ICS) with IL-10–PE-
Cy7, IL–6-PE, TNF–PerCP-Cy5.5 (all from BioLegend),
and anti-human TGF-β1–APC mAb (R&D). Isotype
controls were from BioLegend and R&D. After the cells
were stained, they were washed twice and acquired
within 1 h. For cell-surface LAP staining, B cells were stim-
ulated as described above without the addition of monensin
and stained after non-specific binding (TruStain FcX re-
agent) with anti-human LAP–PE-Cy7 (TGF-β1) (BioLe-
gend) and appropriate PE-Cy7 mouse IgG1 κ isotype-
matched control antibody (BD Biosciences). Samples were
run through a FACS Cyan flow cytometer (Becton Dickin-
son) with standard equipment. Normalized median fluores-
cence intensity (MFI) was calculated by subtracting the MFI
of isotype control antibody-stained cells from the MFI of
specific antibody-stained cells. Gating strategy for B cell phe-
notyping is shown in Additional file 1: Figure S1A.
Analysis of cytokine production
For ELISA assays, B cells (4 × 105) were cultured in
250 μL of serum-free complete X-Vivo 15 medium with
CpG-B 2006 (10 μg/mL) + anti-Ig (10 μg/mL) in 96-well
flat-bottom plates. At 24 h, cell-free supernatants were an-
alyzed for IL-6 and TNF cytokine content using
commercially available Duoset ELISA kits (R&D Systems)
according to the manufacturer’s instructions. The Quanti-
kine Human LAP (TGF-β1) Immunoassay (R&D systems)
was used to measure total TGF-β1 in acid activated cell
culture supernatants. IL-10 cytokine content was analyzed
using the commercially available Kit IL-10 Ready Set-Go
(Ebioscience) according to the manufacturer’s instruc-
tions. The results are expressed as an average of triplicate
wells ± standard error of the mean (SEM).
Reverse-transcription PCR
Highly purified CD19+ B cells (<90% purities) were left
unstimulated or stimulated in the presence of CpG-B
2006 (10 μg/mL) + anti-Ig (10 μg/mL) in 24-well flat-
bottom plates for 3 h at 37 °C. Total RNA was extracted
with TRIzol reagent (Invitrogen), or using ReliaPrep
RNA Cell Miniprep System (Promega) according to the
manufacturer’s instructions, and reverse-transcribed into
cDNA using iScript™ cDNA Synthesis Kit (Bio-Rad
Laboratories). Real-time PCRs were performed using
Power SYBR Green PCR Master Mix Reagent (Applied
Biosystems) on a 7500 Real-time PCR system (Applied
Biosystems). The human TGF-β1 forward and reverse
primers were 5'-CCCAGCATCTGCAAAGCTC-3' and 5'-
GTCAATGTACAGCTGCCGCA-3', alongside primers
targeting the internal normalizer gene β-actin
(Hs_ACTB_2_SG Quantitect Primer Assay, QT01680476;
Qiagen). Relative expression levels were calculated for each
gene using the ΔΔCt method.
Statistical analysis
Data are presented as mean ± SEM. Comparisons
between sample means were performed by Student’s t
test. Values of p < 0.05 were considered statistically
significant.
Results
Induction of IL-10 production by human blood memory B
cells following CpG-B + anti-Ig in vitro stimulation
We assessed the ability of purified human blood B
cells to produce IL-10 under both basal culture
conditions and after stimulation with a combination
of CpG-B, a ligand for human B cell TLR9, and anti-
Ig antibodies. In the basal unstimulated state, IL-10–
producing B cells were barely detected (Fig. 1a–c and
Table 1). After stimulation, low but detectable fre-
quencies of B cells expressing IL-10 were found
(Fig. 1a–c and Table 1). However, the combination of
CpG-B and anti-Ig did not statistically increase the
percentages of CD19+CD27− B cells expressing IL-10
(Fig. 1a–c and Table 1). As previously reported [51],
the frequency of IL-10+ B cells was four to six times
higher in the CD19+CD27+ subpopulation than in the
CD19+CD27− subset (Table 1). The frequency of IL-
10–producing CD19+CD27+ B cells was comparable
to that previously reported [51]. Moreover, we noted
that stimulating circulating B cells with the combin-
ation of activators statistically increased within CD19
+CD27+ B cells the amount of IL-10 produced per
cell (Fig. 1d, e and Table 2). While a similar pattern
was observed for CD19+CD27− B cells expressing IL-
10, the increased levels following B cell stimulation
were not as important (Fig. 1d).
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Increased IL-6 and TNF production in human B cells
stimulated with CpG-B and anti-Ig
We next evaluated the capacity of purified circulating B
cells to produce the proinflammatory cytokines IL-6 and
TNF under basal and stimulated conditions. IL-6
production by B cells is a major pathogenicity factor for
B cells in CNS autoimmunity [3, 5]. TNF is also consid-
ered as an important factor that is secreted by active B
cells in MS [13]. Analysis of frequencies of B cells under
resting conditions revealed that B cells did not produce
Fig. 1 IL-10–producing B cells from human blood. a Frequencies of IL-10-producing B cells from human blood. Cells were cultured with medium
or with combined CpG-B + anti-Ig for 24 h. PMA/ionomycin and monensin were added 5 h before the end of the culture. Cells were stained for surface
CD19 and CD27 and intracellular IL-10 (top panels) or matched isotype control (bottom panels). The representative dot plots show frequencies of IL-10-
producing cells among CD19+CD27− or CD19+CD27+ B cells. b The bar graph indicates mean (± SEM) percentages of B cells that labeled positively for
IL-10 (n = 6). Percentages presented are corrected for isotype control staining. c Line plot of frequencies of IL-10-producing cells among CD19+CD27−
or CD19+CD27+ B cells. Paired data are shown interconnected. d The bar graph indicates quantification (mean ± SEM) of IL-10 staining in both CD19
+CD27− and CD19+CD27+ B cells (n = 6). Geometric mean fluorescence intensities (MFI) were normalized to the isotype control. e The line plot shows
normalized IL-10 MFI by cells among CD19+CD27− and CD19+CD27+ B cells. Paired data are shown interconnected. Significant differences using
Student’s t test between sample means are indicated
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IL-6 (Fig. 2a) or TNF (Fig. 2b). Coordinated stimulation
of BCR and TLR9 however drastically increased IL-6
and TNF levels in these cells. In contrast to IL-10 pro-
duction, which was confined to stimulated CD19+CD27+
B cells, high expression levels of IL-6 and TNF were
found in both CD19+CD27+ and CD19+CD27− subsets.
These data suggest that polyclonal B cell stimulation
shifts B cells towards a proinflammatory dominant
phenotype. In line with these results, B cells from pa-
tients with MS were on average shown to produce more
proinflammatory TNF and IL-6 and less regulatory IL-
10 [5, 17].
BCR ligation together with TLR9 engagement inhibits
TGF-β1 production by human blood B cells
We next assessed the ability of human blood B cells to
express TGF-β1 under our experimental conditions. In
the basal unstimulated state we could readily detect
TGF-β1–producing B cells (Fig. 3a–c and Table 1). The
frequencies of TGF-β1+ B cells were comparable be-
tween the CD19+CD27+ and CD19+CD27− subpopula-
tions. Strikingly, TGF-β1-producing B cell proportions
significantly decreased after the combined CpG and
anti-Ig stimulation (Fig. 3a–c and Table 1). A compar-
able degree of reduction in TGF-β1 expression was ob-
served in both naïve and memory B cells after
stimulation. Furthermore, we noted that stimulating cir-
culating B cells with the combination of activators statis-
tically reduced the expression levels of TGF-β1 per cell,
measured as mean florescence intensity (MFI) (Fig. 3d, e
and Table 2). Taken together these data indicate that
dual BCR ligation and TLR9 engagement induces
substantial decreases in both the frequency of B cells
that express TGF-β1 and the absolute levels of TGF-β1
expression by B cells.
Analysis of cytokines secreted by human blood B cells
after CpG-B and anti-Ig stimulation
We next measured the effect of combined CpG and
anti-Ig stimulation on pro- and anti-inflammatory cyto-
kine secretion by purified B cells. As expected, high
levels of IL-6 (Fig. 4a) and TNF (Fig. 4b) were detected
in supernatants from B cells cultures following stimula-
tion. Likewise, stimulation of B cells also increased IL-10
secretion, although to a much lesser extent (Fig. 4c). As
TGF-β1 is secreted in a latent form, linked to Latency
Associated Protein (LAP) [52], latent TGF-β1 was ana-
lyzed by enzyme-linked immunosorbent assay (ELISA)
after dissociation of TGF-β1 from LAP by acidification
of supernatant samples. This method measures total
TGF-β1, equivalent to dissociated latent TGF-β1 plus
any free TGF-β1 present prior to acidification. Com-
pared to control serum-free conditions, low concentra-
tions of total TGF-β1 were detected in cell-free
supernatants of resting B cells (Fig. 4d). Under these
conditions, levels of total TGF-β1 secreted by resting B
cells was not inferior to those measured by stimulated B
cells (Fig. 4d).
Reduced TGF-β1 expression in human circulating B cells
following activation
As TGF-β1 is produced in a latent form, linked LAP,
and is predominantly expressed on the surface of TGF-
β1-producing cells [52], we next evaluated the cell-
Table 1 Decreased frequencies of TGF-β1-expressing B cells upon in vitro polyclonal stimulation
% IL-10 % TGF-β1 % LAP (TGF-β1)
CD19+ CD27− CD19+ CD27+ CD19+ CD27− CD19+ CD27+ CD19+ CD27− CD19+ CD27+
Unstimulated 0.15 ± 0.09 0.17 ± 0.11 3.54 ± 0.69 4.15 ± 0.56 5.43 ± 1.11 5.40 ± 1.37
[0.00–0.56] [0.00–0.74] [1.80–7.07] [2.82–6.93] [1.74–9.92] [1.58–11.12]
Stimulated 0.81 ± 0.28 4.28 ± 1.02 1.20 ± 0.12 1.86 ± 0.40 3.74 ± 1.19 3.86 ± 1.18
[0.00–1.95] [1.75–9.38] [0.82–1.57] [0.82–3.28] [0.84–9.05] [1.03–8.53]
Values indicate frequencies (mean± SEM) with range (number in parentheses) of cytokine-producing B cells in both CD19+CD27− and CD19+CD27+ B cell subpopulations (n=6).
Frequencies were normalized to the isotype control
Table 2 Activation of human B cells restrains TGF-β1 production
Normalized IL-10 MFI Normalized TGF-β1 MFI Normalized LAP (TGF-β1) MFI
CD19+ CD27− CD19+ CD27+ CD19+ CD27− CD19+ CD27+ CD19+ CD27− CD19+ CD27+
Unstimulated 0.67 ± 0.13 0.89 ± 0.11 0.30 ± 0.02 0.34 ± 0.02 3.06 ± 0.36 2.59 ± 0.40
[0.14–1.10] [0.55–1.37] [0.25–0.38] [0.29–0.44] [2.18–4.75] [1.63–4.32]
Stimulated 1.06 ± 0.10 1.70 ± 0.15 0.15 ± 0.01 0.18 ± 0.02 2.38 ± 0.22 2.27 ± 0.31
[0.70–1.42] [1.25–2.41] [0.11–0.17] [0.13–0.22] [1.78–3.35] [1.52–3.68]
Values indicate quantification (mean ± SEM) with range (number in parentheses) of cytokine staining in both CD19+CD27− and CD19+CD27+ B cells (n = 6).
Geometric mean fluorescence intensities (MFI) were normalized to the isotype control
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surface expression of LAP–TGF-β1 on B cells by flow
cytometry. Comparable frequencies of LAP–TGF-β1+ B
cells were seen in unstimulated CD19+CD27+ and CD19
+CD27− subpopulations (Fig. 5a and Table 1). Remark-
ably, B cell stimulation significantly reduced the percent-
age of CD19+CD27+ and CD19+CD27− B cells bearing
LAP–TGF-β1 (Fig. 5a–c and Table 1). Moreover, we ob-
served a substantial decreased density (MFI) of cell-
surface expression of LAP–TGF-β1 on naïve CD19
+CD27− B cells (Fig. 5d, e and Table 2), which were
significantly more abundant in peripheral blood than
memory B cells (Additional file 1: Figures S1A-B). A
similar trend, with poorer correlation, was observed for
expression levels of LAP–TGF-β1 per cell within the
CD19+CD27+ B cell subpopulation (Fig. 5d, e and
Table 2). Consistent with these data, B cell stimulation
Fig. 2 Combined CpG-B + anti-Ig stimulation potently trigger IL-6 and TNF production by B cells in vitro. Frequencies of (a) IL-6- and (b) TNF-producing B
cells from human blood. Cells were cultured with medium or with combined CpG-B + anti-Ig for 24 h. PMA/ionomycin and monensin were added 5 h before
the end of the culture. Cells were stained for surface CD19 and CD27 and intracellular IL-6 or TNF (top panels) or matched isotype control (bottom panels).
The representative dot plots show frequencies of IL-6- and TNF-producing cells among CD19+CD27− or CD19+CD27+ B cells
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significantly reduced the level of TGF-β1 messenger RNA
(mRNA) by whole CD19+ B cells as measured by quantita-
tive reverse transcription real-time polymerase chain reac-
tion (PCR) (Additional file 1: Figure S1C). Altogether, our
results indicate that activation of human circulating B cells
through BCR/TLR9 co-engagement, a remarkably potent
mechanism of activation of autoreactive B cells [53], shifts
B cells from a regulatory/suppressive phenotype associ-
ated with TGF-β1 expression to a proinflammatory state
characterized by low expression levels of TGF-β1.
Fig. 3 Activation of human B cells negatively regulates TGF-β1 production. a Frequencies of TGF-β1-producing B cells from human blood. Cells
were cultured with medium or with combined CpG-B + anti-Ig for 24 h. PMA/ionomycin and monensin were added 5 h before the end of the culture.
Cells were stained for surface CD19 and CD27 and intracellular TGF-β1 (top panels) or matched isotype control (bottom panels). The representative dot
plots show frequencies of TGF-β1-producing cells among CD19+CD27− or CD19+CD27+ B cells. b The bar graph indicates mean (± SEM) percentages
of B cells that labeled positively for TGF-β1 (n = 6). Percentages presented are corrected for isotype control staining. c Line plot of frequencies of TGF-
β1-producing cells among CD19+CD27− or CD19+CD27+ B cells. Paired data are shown interconnected. d The bar graph indicates quantification (mean
± SEM) of TGF-β1 staining in both CD19+CD27− and CD19+CD27+ B cells (n = 6). Geometric MFI were normalized to the isotype control. e The line plot
shows normalized TGF-β1 MFI by cells among CD19+CD27− and CD19+CD27+ B cells. Paired data are shown interconnected. Significant differences
using Student’s t test between sample means are indicated
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Discussion
Data indicate that depending on the signals B cells re-
ceive, proinflammatory or immunoregulatory cytokines
can be produced, and the shift towards an inflammatory
or a protective/suppressive immune response will occur
[54]. The goal of this investigation was to evaluate the
ability of human blood B cells to produce the classical
pro- and anti-inflammatory cytokines IL-6, TNF, IL-10,
and TGF-β1, respectively, under both basal and stimu-
lated conditions. We found that a combination of adap-
tive signals by BCR cross-linking and innate signals
through TLR9 engagement strongly induced IL-6 and
TNF production by human B cells in vitro. Although
modest, the signals induced by CpG-DNA and BCR
ligation also caused induction of IL-10 production by
memory B cells. Strikingly, stimulation of B cells by
engagement of BCR and TLR9 decreased TGF-β1
production. In regards to the implication of TGF-β1 ex-
pression in regulatory B cell functions in immune toler-
ance [36, 38, 55, 56], the present findings imply that loss
of B cell-derived TGF-β1 production following B cell ac-
tivation may confer increased susceptibility to auto-
immune responses.
Accumulating evidence from both mouse and human
studies confirms the existence of regulatory B cells, and
is beginning to define their mechanisms of action. In
EAE, a CD4+ T cell-mediated autoimmune disease and a
well-established model of MS, data indicate that separate
B cell subsets regulate the induction and recovery of
autoimmune neuroinflammation [35, 57–61]. While ini-
tially all regulatory functions of suppresive B cells were
attributed to their capabilities to produce IL-10, recent
studies have highlighted additional mechanisms by
which Bregs suppress immunity. In addition to the re-
cently reported regulatory role of IL-35-producing B
cells during disease recovery [61], data from our group
have established that TGF-β1-producing B cells restrain
the initiation phase of EAE and the development of
Th17 cells [36]. Consistent with a regulatory role of B
cell-derived of TGF-β1 production in CNS autoimmun-
ity, B cells were previously found to have a central func-
tion in induction of oral tolerance and amelioration of
EAE via the up-regulation of TGF-β in gut associated
lymphoid tissue (GALT) [44, 62]. Moreover, other re-
lated work has reported that TGF-β1 negatively regu-
lates the encephalitogenic capacity of Th17 cells [63]
and EAE [64–66].
Although data indicate that TGF-β1-producing B cells
exert a regulatory function in EAE, their relevance to
MS is yet to be determined. Due to its prominent role in
controlling the immune system [67], TGF-β1 has been
suggested to be one of the central regulatory cytokines
in MS. Interestingly, data obtained from MS patients
have reported that TGF-β expression is increased in
peripheral blood mononuclear cells (PBMCs) from MS
patients with slight or no disability [68] or stable disease
[69]. In a longitudinal study, TGF-β expression was
further shown to decline in relapse and to return to
baseline values four to eight weeks following the MS re-
lapse [70]. Of note, myelin-stimulated peripheral blood
T cell clones from MS patients failed to secrete TGF-β
during acute attacks, while TGF-β expression was re-
stored during disease remission [71]. While no data to
date have investigated TGF-β production by B cells in
MS, our findings, despite being derived from healthy
people, indicate that activation of human blood B cells
reduced their capacity to produce TGF-β1. Considering
the importance of TGF-β1 in modulating immunity and
the abnormal proinflammatory polarization of B cells of
MS patients [5, 6, 13, 17], inefficient production of TGF-
β1 by B cells may be associated with an increased risk of
developing MS or driving new relapsing MS disease
activity. It is also tempting to postulate that exacerbation
of symptoms, or onset of new pathologies following B
cell depletion with Rituximab in a few patients with
immune-mediated diseases [26–29], could be associated
with the depletion of unactivated TGF-β1-producing
B cells. Future studies aimed at evaluating TGF-β1
Fig. 4 Stimulation of B cells elicits secretion of IL-6, TNF, and IL-10, but not TGF-β1. Purified B cells from human blood were cultured with serum-free
medium alone or with combined CpG-B + anti-Ig for 24 h. The amount of (a) IL-6, (b) TNF, (c) IL-10, and (d) total TGF-β1 protein in the culture cell-free
supernatants was determined by ELISA. Bar graphs show mean cytokine concentrations (± SEM) from technical triplicates from one representative
donor out of two analyzed
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production by B cells, regardless of their antigenic
specificity, from MS subjects and healthy controls in
response to modes of activation relevant to B-cell–T-
cell interaction and MS [13, 17, 72] will allow for a bet-
ter understanding of the contribution of B cell-derived
TGF-β1 in this disease.
The phenotypic characterization of human IL-10-
producing B cells has been integral in accelerating as-
sessment of their function and relevance in immune-
mediated diseases [73]. B cells isolated according to the
cell surface expression of receptors classically used to
separate known B cell subsets have revealed that CD19
Fig. 5 Stimulation of B cells restrains LAP expression. a Frequencies of LAP-producing B cells from human blood. Cells were cultured with
medium or with combined CpG-B + anti-Ig for 24 h. PMA/ionomycin was added 5 h before the end of the culture. Cells were stained for surface
CD19, CD27, and LAP (top panels) or matched isotype control (bottom panels). The representative dot plots show frequencies of LAP–expressing
cells among CD19+CD27− or CD19+CD27+ B cells. b The bar graph indicates mean (± SEM) percentages of B cells that labeled positively for LAP
(n = 6). Percentages presented are corrected for isotype control staining. c Line plot of frequencies of LAP-expressing cells among CD19+CD27− or CD19
+CD27+ B cells. Paired data are shown interconnected. d The bar graph indicates quantification (mean± SEM) of LAP staining in both CD19+CD27− and CD19
+CD27+ B cells (n= 6). Geometric MFI were normalized to the isotype control. e Line plot shows normalized LAP MFI by cells among CD19+CD27− and CD19
+CD27+ B cells. Paired data are shown interconnected. Significant differences using Student’s t test between sample means are indicated
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+CD27− naïve-like B cells produced more IL-10 than
CD19+CD27+ B cells after stimulation via BCR and
CD40 [17]. In a separate study, it was shown that the
proportion of IL-10-producing B cells was higher in the
CD19+CD27+ subpopulation than in the CD19+CD27−
subset after stimulation with CpG-DNA and BCR
ligation [51]. These different results may stem from the use
of distinct stimulatory conditions. Here, our data confirm
that IL-10-producing B cells activated via BCR and TLR9
fall within the CD19+CD27+ subpopulation [51]. Using
CD27 as a surrogate marker of human memory B cells, our
data demonstrate that TGF-β1-producing B cells do not be-
long to a unique B cell subset. The characterization of hu-
man TGF-β1-producing B cells may provide a better
understanding of their function and development. Interest-
ingly, the quantification of TGF-β1 expression by B cells in
EAE mice [36] indicate that murine TGF-β1-producing B
cells do not belong to the CD1dhiCD5+ B10 subset [74] or
CD138+ plasma cells, which have been shown to be the
main source of IL-10 and IL-35 during disease development
[61, 75].
Conclusions
In summary, our data demonstrate that B cell activation
by BCR/TLR9 co-engagement differentially regulates the
production of pro- and anti-inflammatory cytokines by
human B cells. B cell stimulation with combined CpG-B
+ anti-Ig induced strong IL-6 and TNF production. IL-10
was modestly elevated after B cell activation. Remarkably,
B cells stimulated in this way had a significantly reduced
capacity to produce TGF-β1. These findings imply that ac-
tivation of human B cells may amplify autoimmune re-
sponses by restricting the regulatory functions of resting
TGF-β1-producing B cells and favoring the proinflamma-
tory activities of B cells. These observations further sup-
port the consensus that the action of naïve B cells is
fundamentally regulatory and that activated B cells prefer-
entially produce proinflammatory cytokines [6, 17].
Additional files
Additional file 1: Figure S1. B cell activation reduced TGF-β1 mRNA
expression. a A representative gating of naïve and memory B cells in
PBMCs is shown. Cells were first gated for singlets (FSC-H vs. FSC-A) and
lymphocytes (SSC-A vs. FSC-A), followed by a live/dead gate. Naïve B cells
(CD27–) and resting and activated memory B cells (CD27+) were distin-
guished by CD19 versus CD27 gating. FSC-H, forward scatter height; FSC-
A, forward scatter area; SSC-A, side scatter area. b Scatter plot indicates
mean (± SEM) percentages of naïve (CD27–) versus memory (CD27+) B cell
subpopulations (n = 6). c Quantitative RT-PCR analysis of human B cells for
the expression of TGF-β1. Expression levels are normalized using the ΔΔCt
method, relative to β-actin. Results show mean of 6 independent sets of
samples. Errors bars represent SEM. (DOCX 286 kb)
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